Influenza virus has significant viral diversity, both through antigenic drift and shift, which
makes development of a vaccine challenging. Current influenza vaccines are updated …

The conventional approach for designing vaccine against a particular disease involves
stimulation of the immune system using the whole pathogen responsible for the disease. In …

The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine
development,. Antigens derived from natural HIV-1 sequences have elicited only a limited …

Abstract The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and
recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine …

The global spread of human immunodeficiency virus (HIV) and the human suffering left in its
wake have made AIDS a global heath priority. Yet the capacity of HIV to mutate and evolve …

Highlights•Immune correlates of protection are guiding HIV-1 vaccine development.•RV144
follow-on trials aim to generate antibody responses to the V1V2 region of Env.•Immunogens …

Despite 30 years of effort, we do not have an effective HIV-1 vaccine. Over the past decade,
the HIV-1 vaccine field has shifted emphasis toward antibody-based vaccine strategies …

A key unresolved challenge for developing an effective HIV‐1 vaccine is the discovery of
strategies to elicit immune responses that are able to cross‐protect against a significant …

A global human immunodeficiency virus‐1 (HIV‐1) vaccine will have to elicit immune
responses capable of providing protection against a tremendous diversity of HIV‐1 variants …

Rabies is an ancient neglected tropical disease that causes tens of thousands of human
deaths and millions of cattle deaths annually. In order to develop a new vaccine for potential …